Skip to main content
$0.091 0.002 (2.25%)

High

$0.10

Low

$0.09

Trades

2,797

Turnover

$4,713,392

Volume

50,159,971
30 June 2023 at 4:59pm
If you were already registered, log in here.

Short Interest

ASIC data, 6 Nov 2026

% Shorted

0.33% 0.01
vs 0.34% prior report

Most Shorted Rank

364th
of 717 shorted ASX stocks

Peak Short

8.10%
Aug 2023

Days to Cover

0.6
at 50d avg vol
Subject
IMU Ann: Issuance of Milestone Shares Under Vaxinia Acquisition

IMU Ann: Change of Director's Interest Notice - LR

IMU Ann: Imugene Presents HER-Vaxx Update at ESMO World GI Congress

IMU Ann: FDA IND APPROVAL OF NEW ONCOLYTIC VIROTHERAPY CHECKVACC

IMU Ann: Application for quotation of securities - IMU

IMU Ann: Application for quotation of securities - IMU

IMU Ann: Notice Under Section 708A

IMU Ann: Application for quotation of securities - IMU

IMU Ann: Notification regarding unquoted securities - IMU

IMU Ann: Proposed issue of securities - IMU

IMU Ann: Investor Presentation

IMU Ann: Investor Webinar Presentation Clarification

IMU Ann: Investor Webinar Presentation

IMU Ann: Imugene Appoints Dr Monil Shah as Chief Business Officer

IMU Ann: Appendix 2A

IMU Ann: Proposed issue of Securities - IMU

IMU Ann: Change of Director's Interest Notice - LC

IMU Ann: Appendix 2A

IMU Ann: Proposed issue of Securities - IMU

IMU Ann: Managing Director and CEO increases shareholding in Imugene

IMU Ann: Change of Director's Interest Notice - PH

IMU Ann: Change of Director's Interest Notice - LC

IMU Ann: Change of Director's Interest Notice - CW

IMU Ann: Appendix 2A

IMU Ann: Proposed issue of Securities - IMU

IMU Ann: CEO & Executive Chairman increases IMU shareholding

IMU Ann: Appendix 2A

IMU Ann: Proposed issue of Securities - IMU

IMU Ann: Investor Webinar Details

IMU Ann: Investor Presentation

IMU Ann: IMUGENE LICENSES CAR T DIRECTED OV THERAPY FOR SOLID TUMOURS

IMU Ann: Appendix 2A

IMU Ann: Proposed issue of Securities - IMU

IMU Ann: Appendix 2A

IMU Ann: Proposed issue of Securities - IMU

IMU Ann: Appendix 2A

IMU Ann: Proposed issue of Securities - IMU

IMU Ann: Prestigious Research Journal Publish HER-Vaxx Phase 1B Data

IMU Ann: Appendix 4C - quarterly

IMU Ann: Imugene announces clinical milestone for HER-Vaxx

IMU Ann: Appendix 2A

IMU Ann: Proposed issue of Securities - IMU

IMU Ann: Imugene Oncolytic Virus Presentation at AACR 2021 Meeting

IMU Ann: Imugene HER-Vaxx Presentation at AACR 2021 Meeting

IMU Ann: Final Highest Dose in Phase 1 Clinical Trial of PD-VAXX

IMU Ann: Appendix 2A

IMU Ann: Proposed issue of Securities - IMU

IMU Ann: S&P DJI Announces March 2021 Quarterly Rebalance

IMU Ann: Appendix 3G

IMU Ann: Imugene to Present Oncolytic Virus Data at AACR21 Meeting

If you were already registered, log in here.

Similar Companies

CSL ...
CSL
CUV
IMM
MSB
OPT
PAR
PYC
RAC
TLX
S88
MAV
CX8
MTX $12m raise
ATW $7.5m raise
RDO $30m raise
ABC $5m raise
RGS